Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR2 | Q969V1 | 8/20 | 0.47 |
| ▸ | DRD2 | P14416 | 8/20 | 0.47 |
| ▸ | DRD3 | P35462 | 5/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 4/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12999742 | 0.94 | MCHR2 (0.46) | MCHR2DRD2DRD3SLC6A4KCNH2 | |
| SCHEMBL13001599 | 0.90 | MCHR2 (0.46) | MCHR2DRD2DRD3SLC6A4KCNH2 | |
| SCHEMBL13001087 | 0.90 | MCHR2 (0.46) | MCHR2DRD2DRD3SLC6A4KCNH2 | |
| SCHEMBL13000662 | 0.90 | DRD2 (0.47) | MCHR2DRD2DRD3SLC6A4KCNH2 | |
| SCHEMBL2991360 | 0.90 | MCHR2 (0.48) | MCHR2DRD2DRD3SLC6A4KCNH2 | |
| SCHEMBL13000329 | 0.89 | SIGMAR1 (0.56) | MCHR2SIGMAR1 | |
| SCHEMBL13001195 | 0.89 | SIGMAR1 (0.56) | MCHR2SIGMAR1 | |
| SCHEMBL13001179 | 0.88 | MCHR2 (0.43) | MCHR2DRD2DRD3SLC6A4KCNH2 | |
| SCHEMBL13001455 | 0.88 | SIGMAR1 (0.54) | MCHR2DRD2SLC6A4KCNH2SIGMAR1 | |
| SCHEMBL13208088 | 0.87 | MCHR2 (0.44) | MCHR2DRD2DRD3SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367691-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367691-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100311746-A1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311746-A1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| US-7786141-B2 | Dihydrospiroindene modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786141-B2 | Dihydrospiroindene modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-20070043023-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070043023-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311746-A1 | MODULATORS OF MUSCARINIC RECEPTORS | CHRM3, CHRM5, CHRM2 | MCHR2 159/4885DRD2 757/4885DRD3 1007/4885 |
| US-20070043023-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | MCHR2 159/4885DRD2 757/4885DRD3 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.